| Display title | Chemistry:Aticaprant |
| Default sort key | Aticaprant |
| Page length (in bytes) | 24,061 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 327945 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>JTerm |
| Date of page creation | 03:28, 9 March 2024 |
| Latest editor | imported>JTerm |
| Date of latest edit | 03:28, 9 March 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder. A regulatory application for approval of the medication is expected to be submitted by 2025. Aticaprant... |
